Cargando…

The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study

BACKGROUND: Although immune checkpoint inhibitor (ICI) monotherapy remains the standard of second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) , the objective response rate (ORR) is low. There is an urgent need to increase the response population of second-line immuno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Bolin, Wang, Jingyi, Pu, Xingxiang, Li, Jia, Wang, Qianzhi, Liu, Liyu, Xu, Yan, Xu, Li, Kong, Yi, Li, Kang, Xu, Fang, Liang, Shuzhi, Cardona, Andrés F., Wu, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641046/ https://www.ncbi.nlm.nih.gov/pubmed/36386462 http://dx.doi.org/10.21037/tlcr-22-697

Ejemplares similares

Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study
por: Pu, Xingxiang, et al.
Publicado: (2022)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
por: Jiang, Meilin, et al.
Publicado: (2020)

Case Report: Tissue Origin Identification for Cancer of Unknown Primary: Gene Expression Profiling Approach
por: Pu, Xingxiang, et al.
Publicado: (2021)

miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9
por: WU, LIN, et al.
Publicado: (2016)

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
por: Granet-Vaissiere, Estelle, et al.
Publicado: (2023)

IL-18 serves as a main effector of CAF-derived METTL3 against immunosuppression of NSCLC via driving NF-κB pathway
por: Xu, Li, et al.
Publicado: (2023)

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
por: Qian, Xinye, et al.
Publicado: (2022)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
por: Pu, Xingxiang, et al.
Publicado: (2023)

Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma
por: Jiang, Meilin, et al.
Publicado: (2022)

Influence factors of the survival in colorectal cancer patients with second primary malignancy after surgery: A SEER database analysis
por: Liu, Liyu, et al.
Publicado: (2023)

Future options of anti-angiogenic cancer therapy
por: Cao, Yihai
Publicado: (2016)

A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer
por: Zhang, Baihua, et al.
Publicado: (2022)

Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
por: Zheng, Li, et al.
Publicado: (2022)

OPN Promotes Cell Proliferation and Invasion through NF-κB in Human Esophageal Squamous Cell Carcinoma
por: Chen, Bolin, et al.
Publicado: (2022)

EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade
por: Tabasum, Saba, et al.
Publicado: (2023)

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
por: Xu, Gehan, et al.
Publicado: (2022)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
por: Ciciola, Paola, et al.
Publicado: (2020)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

The evaluation of anti-angiogenic effects of Endostar on rabbit VX2 portal vein tumor thrombus using perfusion MSCT
por: Feng, Guoquan, et al.
Publicado: (2014)

Involvement of COX-2/PGE(2) signalling in hypoxia-induced angiogenic response in endothelial cells
por: Zhao, Lixing, et al.
Publicado: (2012)

Credit assignment in hierarchical option transfer
por: Li, Jing-Jing, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
por: Xian, Feng, et al.
Publicado: (2022)

Anti-Angiogenic Effect of Triptolide in Rheumatoid Arthritis by Targeting Angiogenic Cascade
por: Kong, Xiangying, et al.
Publicado: (2013)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review
por: Koshkin, Vadim S., et al.
Publicado: (2021)

Perivascular epithelioid cell tumor of the lung: A case report and literature review
por: Yu, Shaofu, et al.
Publicado: (2022)

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
por: Frentzas, Sophia, et al.
Publicado: (2016)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)

Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer
por: Chen, Bolin, et al.
Publicado: (2021)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
por: Song, Yuxiao, et al.
Publicado: (2020)

Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option
por: Ren, Yi, et al.
Publicado: (2022)

Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer
por: Chen, Dongna, et al.
Publicado: (2023)

Options for Teens with No Options: A Self-Managed Second Trimester Abortion
por: Duroseau, Nathalie, et al.
Publicado: (2021)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma—a suitable treatment option: case report and review of anti-angiogenic treatment options
por: Semenisty, Valeriya, et al.
Publicado: (2015)

Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis
por: Sun, Tuanhe, et al.
Publicado: (2021)

ANGI-05 PATHOGENESIS OF RESISTANCE (MIMICRY AND CO-OPTION) TO ANTI-ANGIOGENIC TREATMENT FOR GLIOBLASTOMA
por: Takano, Shingo, et al.
Publicado: (2019)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
por: Maharjan, Ruby, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sla3daedamhvrbrgj2p8arfadg